Case for a drug dispensing device

Abstract

Provided is a case for a drug dispensing device that ensures easy removal of components such as needles and cartridges. 【Solution means】The case 1 has a first half shell 11 and a second half shell 12. The half shells 11 and 12 are connected by a hinge so as to be closable. The second half shell is configured to open and close the first half shell. The first half shell and the second half shell have a plurality of corresponding recesses 2, 6 configured to receive a drug dispensing device or a component of the drug dispensing device. At least one of the plurality of recesses 2 in the first half shell has an inclination point. When the drug dispensing device or a part of the drug dispensing device is received in the recess, a distance is formed on one side of the inclination point between the drug dispensing device or a part of the drug dispensing device and the bottom of the recess.

Description

Technical Field

[0001] The present disclosure relates to a case for a drug dispensing device, particularly for an injection device.

[0002] A drug dispensing device, particularly a multi-part drug dispensing device, can be provided in a case or box that can accommodate individual components such as needles and cartridges. However, it may be difficult for patients with limited hand strength to grip and remove the components from the case. Furthermore, the space is often not optimally utilized.

[0003] Therefore, it is necessary to provide a case that ensures easy removal of the components. Furthermore, the use of the space within the case can be improved.

[0004] This object is achieved by the present disclosure.

[0005] The invention is defined in the independent claims. The dependent claims describe preferred embodiments.

[0006] The present disclosure relates to a case for a drug dispensing device having a first half-shell and a second half-shell. The half-shells are connected in a closable manner by a hinge, and the second half-shell is configured to open and close the first half-shell. The first half-shell and the second half-shell have a plurality of corresponding recesses configured to receive a drug dispensing device or a part of the drug dispensing device. At least one of the plurality of recesses in the first half-shell has an inclination point. When a drug dispensing device or a part of the drug dispensing device is received in the recess, a distance is formed between the drug dispensing device or the part of the drug dispensing device and the bottom of the recess on one side of the inclination point.

[0007] Preferred embodiments further include the following features.

[0008] Preferably, the lowest point of at least one of the plurality of recesses is deeper than the inclination point.

[0009] Preferably, the tipping point is formed by ribs disposed within the recess.

[0010] Preferably, a plurality of ribs are disposed within the recess, and the tipping point is formed by the contour of the ribs.

[0011] Preferably, the hinge is a double living hinge.

[0012] Preferably, more than half of the volume of the drug dispensing device or a part of the drug dispensing device is accommodated within the first half shell.

[0013] Preferably, at least one of the plurality of recesses, in particular the bottom surface of at least one of the plurality of recesses, is inclined at an acute angle with respect to the plane of the hinge.

[0014] Preferably, the case is a rigid shell.

[0015] Preferably, the case is formed as a single piece.

[0016] Preferably, the case is formed by thermoforming or injection molding.

[0017] The case is preferably transparent or translucent.

[0018] Preferably, the first and second half shells can be connected by a snap connection or a latch connection.

[0019] Preferably, the tipping point is asymmetrically disposed within the recess. Preferably, the tipping point divides the recess into a longer portion and a shorter portion.

[0020] Preferably, the distance is formed in the shorter portion.

[0021] Preferably, the recess is configured to receive an injection device and / or a syringe and / or a cartridge and / or a needle protection device.

[0022] Preferably, each of the recesses substantially follows the shape of the injection device and / or the syringe and / or the cartridge and / or the needle protection device.

[0023] Preferably, the case has integral markings or writing. Preferably, the markings or writing are formed during the molding process.

[0024] Preferably, at least one of the plurality of recesses further has a laterally disposed removal recess for gripping the drug dispensing device or a part of the drug dispensing device.

[0025] When the term "distal direction" is used in this disclosure, it refers to the direction away from the dose delivery site during use of the drug dispensing device. When the term "distal part / distal end" is used, this refers to the part / end of the dispensing device or the part / end of an element thereof that is furthest from the dose delivery site during use of the drug dispensing device. Correspondingly, the term "proximal direction" refers to the direction towards the dose delivery site during use of the drug dispensing device. When the term "proximal part / end" is used, this refers to the part / end of the dispensing device, or the part / end of an element thereof that is closest to the dose delivery site during use of the drug dispensing device.

[0026] Furthermore, the terms "longitudinal direction" and "axial direction" refer to the direction extending along the device or its component from the proximal end to the distal end, typically in the direction (z-axis) of the longest dimension of the device and / or the component.

[0027] Similarly, the terms "cross-section" and "cross" refer to the direction substantially perpendicular to the longitudinal direction (x-axis and y-axis).

[0028] Furthermore, the term "circumference" or "circumferential direction" refers to the circumference or circumferential direction with respect to an axis extending in the direction (z-axis) of the longest dimension of the device and / or the component, typically the central axis. Similarly, the "radial direction" refers to the direction extending radially with respect to the axis, and "rotation" and "rotating" refer to rotation with respect to the axis.

[0029] Generally, all terms used in the claims should be construed in accordance with their ordinary meanings in the relevant technical field, unless explicitly defined otherwise in this specification. All references to elements, devices, components, constituent elements, means, etc. should be construed broadly as referring to at least one instance of the element, device, component, constituent element, means, etc., unless explicitly defined otherwise.

Brief Description of the Drawings

[0030] In the following figures, the same or similar elements are denoted by the same reference numerals. The drawings are as follows.

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5A

Figure 5B

Figure 6

Figure 7

Figure 8

Figure 9A

Figure 9B

Figure 10

Figure 11

[0031] Figure 1 shows the case 1 for a drug dispensing device or an element (not shown) thereof according to one embodiment in a closed state. Hereinafter, the drug dispensing device may also be referred to as an injection device or an injection pen, but the present disclosure is suitable for various other drug dispensing devices. Further, the drug dispensing device can be accommodated in a plurality of individual parts within the case 1. The parts of the drug dispensing device may also be referred to as elements (plural) or parts (plural). Further, the case 1 can also be referred to as a box, a kit, etc.

[0032] The case 1 has a first half-shell 11 and a second half-shell 12 which are connected in a closable manner by a hinge 4. The first half-shell 11 has a plurality of recesses 2, and the second half-shell 23 has a plurality of corresponding recesses 6. In the closed state, as shown in Figure 1, these recesses 2 and 6 can be seen as bulges.

[0033] The recess 2 is configured to receive the drug dispensing device 5 or an element 5 of the drug dispensing device (see below). The terms drug dispensing device and element may be used synonymously hereinafter. In particular, the element can be received between the recess 2 of the first half-shell 11 and the corresponding recess 6 of the second half-shell 12.

[0034] The case may have a closure 3. The closure 3 can be designed as a snap connection, a latch connection, etc.

[0035] The closure 3 can be designed symmetrically, for example, by two lateral latching bars on the second half-shell 12 and a central latching bar on the first half-shell 11, or vice versa (see Figure 1). The symmetrical arrangement can simplify the operation for ambidextrous people.

[0036] Figure 2 shows a top view of the case 1 of Figure 1. Again, the recesses 2 and / or the corresponding recesses 6 are visible as raised portions from the outside when closed.

[0037] Figure 3 shows a cross-section along line A-A (x-z plane) of Figure 2. This cross-section passes through the centers of the two recesses 2 and / or the corresponding recesses 6 of Case 1 and shows Case 1 in a closed and empty state. In this embodiment, the recess 2 shown can be used for the needle guard and the cartridge holder.

[0038] The first half shell 11 can have one or more additional removal recesses 23 to make the removal of the element even easier. The removal recess(es) 23 can enable the drug delivery device or a part of the drug delivery device to be gripped and removed.

[0039] Figure 4 shows a cross-section along line B-B (x-z plane) of Figure 2 passing through the center of the recess 2. The large recess 2 can accommodate, for example, an injection pen.

[0040] The recess 2 can have an inclination point 21 which can also be called a fulcrum or pivot point. The inclination point 21 can be arranged within the recess such that a distance is formed between the bottom of the recess 2 and the drug delivery device or an element thereof (not shown) when the drug delivery device or an element thereof is received within the recess 2.

[0041] In the case of a tapered drug delivery device or an element thereof, this can be achieved, for example, by a recess 2 having a flat bottom. The bottom is the lowest point in the (negative) z-axis direction along the x-axis. A flat bottom refers herein to the bottom of a recess extending substantially parallel to the x-y plane.

[0042] In the case of a substantially straight drug delivery device or an element thereof, the recess can be designed such that the deepest point of the recess 2 is lower than the inclination point 21.

[0043] The inclination point 21 can be arranged asymmetrically or symmetrically within the recess 2. This means that the inclination point 21 can divide the recess 2 into halves in the x-axis direction or into unequal parts. In the figure, as an example, the inclination point 21 is provided to the left of the center of the corresponding recess 2 (offset in the negative x-axis direction with respect to the center).

[0044] Figures 5A and 5B illustrate the principles of the present disclosure. These figures correspond to the figures of FIG. 3, but are cross-sectional views through the open case 1 with the elements of the drug dispensing device 5 inserted. The dark regions indicate the cross-sectional areas.

[0045] As can be seen from FIG. 5A, in the initial state, a distance d is formed between the element of the drug dispensing device 5 and the bottom of the recess 2. In the figure, the distance d is shown to the left of the tipping point 21, but this should not be understood as limiting. The element 5 is placed substantially horizontally within the case 1.

[0046] If the user wants to remove the element 5, pressure can be applied to one end of the element 5 (the left end in FIGS. 5A and 5B; see the arrow in the negative z-axis direction). In this example, pressure is applied to the proximal end of the element 5, but depending on the arrangement of the tipping point 21, pressure can also be applied to the distal end of the element 5.

[0047] Due to the distance d between the element 5 and the bottom of the recess 2, the element 5 tilts around the tipping point 21 due to the applied pressure, and as a result, the other end of the element 5, the right end in the figure, is lifted out of the recess 2. This makes it easier to grip and remove the element 5 from the case 1. In FIG. 5B, there is no longer a distance between the element 5 and the bottom of the recess. However, in order to facilitate the removal of the element 5, the distance can also be reduced only partially.

[0048] The recess 2 or the tipping point 21 can be provided according to the desired tilt angle. The larger the initial distance d between the element 5 and the bottom of the recess 2, the larger the lifting angle of the element 5 for removal can be.

[0049] FIG. 6 shows a perspective view of the open empty case 1 as described above. Gripping recesses 23 can be provided at at least one end of at least one of the recesses 2, whereby the user can lift or grip each element 5. These gripping recesses 23 can be provided in addition to the tipping point 21.

[0050] As the tilting point 21, as shown in the perspective view of FIG. 7, the rib 22 can also be provided in the recess 2. The rib 22 can be provided in a flat or irregular recess 2. The rib 22 may extend along at least a part of the inner peripheral surface of the recess 2. Further, the rib 22 may extend at least downward (negative z-axis direction) of the recess 2 along at least a part of the inner peripheral surface of the recess 2.

[0051] Since the rib 2 forms a distance d between the element 5 and the bottom of the recess, when pressure is applied to one end, the element 5 rotates (tilts) about the tilting point or the rib 22, and the other end is lifted. This corresponds to the operating principle described above and simplifies the removal of the element 5.

[0052] FIG. 8 is a cross-sectional view taken along line D-D (x-z plane) of FIG. 7, showing the empty recess 2 provided with the rib 22.

[0053] FIGS. 9A and 9B show cross-sections of FIG. 8 with the element 5 inserted. As described with reference to FIGS. 5A and 5B, the element 5 can tilt about the rib 22 (tilting point) by the pressure from above.

[0054] As shown in FIG. 10, the rib 22 may be designed with a plurality of parts and may extend over two or more sectors of the inner peripheral surface of the recess 2. The operating principle in this case is the same as above. The tilting point 21 can be formed by the contour of the rib 22.

[0055] FIG. 11 is a cross-sectional view taken along line C-C (x-z plane) shown in FIG. 2. The recess 2 shown therein can be tilted at an angle μ with respect to the hinge (x-y plane). This not only simplifies the removal but also allows the element 5 (not shown) to be arranged to overlap within the case 1, thereby improving the use of space.

[0056] The angle μ can be an acute angle of 10° to 45°, preferably 20° to 35°.

[0057] In the above-described embodiment, most of the volume of the drug dispensing device 5 or its element 5 is accommodated within the first half-shell 11. In other words, the recess 2 of the first half-shell 11 is deeper than the corresponding recess 6 of the second half-shell 12. However, half of the drug dispensing device 5 or its element 5 may be substantially accommodated within the first half-shell 11 or the second half-shell 12. Alternatively, the second half-shell 12 may also accommodate most of the drug dispensing device 5 or its element 5.

[0058] The recess 2 can have different shapes within the first half-shell 11 and can be configured to receive different elements 5. Each of the recesses 2 can substantially follow the shape of the drug dispensing device or its element 5. Alternatively, the recess 2 may be formed as a substantially cylindrical or rectangular recess 2. The above also equally applies to the corresponding recess 6.

[0059] The recess 2 can be shaped so that the corresponding element 5 is held therein.

[0060] In one embodiment, the deepest point of the recess 2 may be deeper than the inclination point 21. In other words, at least one point of the recess 2 may be deeper than the portion of the element 5 received within the recess 2.

[0061] Depending on the shape of the element 5 accommodated in the recess, the inclination point 21 may be in the same plane as the deepest point of the recess 2. This plane can extend parallel to the x-y plane.

[0062] Case 1 can be designed as a rigid shell (a "rigid case"). Further, case 1 can be designed as a single part. Case 1 can be manufactured from plastic by injection molding or thermoforming. Case 1 can be transparent or translucent. Further, during the molding process, writing or markings can be incorporated into the first and / or second half-shells 11, 12.

[0063] The hinge 4 can be designed as a double living hinge (see Fig. 7). This has the advantage that when the case 1 is opened, it remains at an opening angle of 180° and does not close partially or completely again due to the elasticity of the hinge.

[0064] Furthermore, the case 1 can have a flat back or a hinge side by means of a double living hinge. This can be advantageous for storage and transportation.

[0065] The first and second half-shells 11, 12 can also be made of two parts and can be connected by wires, screw hinges, or adhesive hinges.

[0066] In one embodiment of the present disclosure, a case 1 for a drug dispensing device is described. The case 1 has a first half-shell 11 and a second half-shell 12. The half-shells 11, 12 are connected in a closable manner by a hinge 4, and the second half-shell 12 is configured to open and close the first half-shell 11. The first half-shell 11 and the second half-shell 12 have a plurality of corresponding recesses 2, 6 configured to receive the drug dispensing device 5 or parts of the drug dispensing device 5. At least one of the plurality of recesses 2 in the first half-shell 11 has an inclination point 21. When the drug dispensing device 5 or a part of the drug dispensing device 5 is received in the recess 2, a distance d is formed between the drug dispensing device 5 or a part of the drug dispensing device 5 and the bottom of the recess 2 on one side of the inclination point 21.

[0067] In one embodiment, the lowest point of at least one of the plurality of recesses 2 is deeper than the inclination point 21.

[0068] In one embodiment, the inclination point 21 is formed by a rib 22 disposed in the recess 2.

[0069] In one embodiment, a plurality of ribs 22 are disposed in the recess 2, and the inclination point 21 is formed by the contour of the rib 22.

[0070] In one embodiment, the hinge 4 is a double living hinge.

[0071] In one embodiment, more than half of the volume of the drug dispensing device 5 or a part of the drug dispensing device 5 is accommodated within the first half-shell 11.

[0072] In one embodiment, at least one of the plurality of recesses 2, in particular the bottom surface of at least one of the plurality of recesses 2, is inclined at an acute angle μ with respect to the plane of the hinge 4 or the living hinge.

[0073] In one embodiment, the case 1 is a rigid shell.

[0074] In one embodiment, the case 1 is formed as a single piece.

[0075] In one embodiment, the case 1 is formed by thermoforming or injection molding.

[0076] In one embodiment, the case 1 is transparent or translucent.

[0077] In one embodiment, the first and second half-shells 11, 12 can be connected by a snap connection or a latch connection.

[0078] In one embodiment, the tipping point 21 is asymmetrically arranged within the recess 2. In one embodiment, the tipping point 21 divides the recess 2 into a longer part and a shorter part.

[0079] In one embodiment, the distance d is formed in the shorter part.

[0080] In one embodiment, the recess 2 is configured to receive an injection device and / or a syringe and / or a cartridge and / or a needle protection device.

[0081] In one embodiment, each of the recesses 2 substantially follows the shape of an injection device and / or a syringe and / or a cartridge and / or a needle protection device.

[0082] In one embodiment, the case 1 has an integral marking or writing. In one embodiment, the marking or writing is formed during the molding process.

[0083] In one embodiment, at least one of the plurality of recesses 2 further has a laterally disposed removal recess 23 for gripping the drug dispensing device 5 or a part of the drug dispensing device 5.

[0084] Although the present invention has been illustrated and described in detail by the drawings and the related description, this illustration and this detailed description should be understood as illustrative and exemplary, and should not be understood as limiting the present invention. Those skilled in the art should understand that changes and modifications can be made without departing from the scope of the claims. In particular, the present invention also includes embodiments having any combination of the features mentioned or shown above in various aspects and / or embodiments.

[0085] The present invention also includes those features, even if the individual features in the figures are shown in relation to other features and / or not mentioned above.

[0086] Furthermore, the term "comprise" and its derivatives do not exclude other elements or steps. Similarly, the indefinite articles "a" or "an" and their derivatives do not exclude a plurality. The functions of the plurality of features listed in the claims can be realized by a single entity. Terms such as "substantially", "about", "approximately" related to a characteristic or value also do not precisely define the characteristic or value. The reference signs in the claims should not be construed as limiting the scope of the claims.

[0087] The dispensing device described herein can be used for the treatment and / or prevention of one or more of many different types of disorders.

[0088] Examples of diseases include, but are not limited to, rheumatoid arthritis, inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis), hypercholesterolemia and / or lipid metabolism disorders, cardiovascular disease, diabetes (e.g., type 1 diabetes or type 2 diabetes), psoriasis, psoriatic arthritis, spondyloarthritis, hidradenitis suppurativa, Sjogren's syndrome, migraine, cluster headache, multiple sclerosis, neuromyelitis optica spectrum disorder, anemia, thalassemia, paroxysmal nocturnal hemoglobinuria, hemolytic anemia, hereditary angioedema, systemic lupus erythematosus, lupus nephritis, myasthenia gravis, Behcet's disease, hemophagocytic syndrome, atopic dermatitis, retinal diseases (e.g., age-related macular degeneration, diabetic macular edema), uveitis, infectious diseases, bone diseases (e.g., osteoporosis, osteopenia), asthma, chronic obstructive pulmonary disease, thyroid diseases, nasal polyps, transplantation, acute hypoglycemia, obesity, anaphylaxis, allergies, sickle cell anemia, Alzheimer's disease, Parkinson's disease, Lewy body dementia, systemic infusion reactions, immunoglobulin E (IgE)-mediated hypersensitivity reactions, cytokine release syndrome, immunodeficiency (e.g., primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy), enzyme deficiency disorders (e.g., Pompe disease, Fabry disease, Gaucher disease), growth factor deficiency disorders, hormone deficiency disorders, coagulation disorders (e.g., hemophilia, von Willebrand disease, factor V Leiden), and cancer.

[0089] Examples of drug types that may be included in the dispensing device described herein include, but are not limited to, small molecules, hormones, cytokines, blood products, enzymes, vaccines, anticoagulants, immunosuppressants, antibodies, antibody-drug conjugates, neutralizing antibodies, antagonists, radioligand therapy, radioisotopes and / or radiopharmaceuticals, diagnostic agents, bispecific antibodies, proteins, fusion proteins, peptides, polypeptides, PEGylated proteins, protein fragments, nucleotides, protein mimetics, protein variants, protein precursors, protein derivatives, chimeric antigen receptor T cell therapy, cell or gene therapy, oncolytic viruses, or immunotherapy.

[0090] Exemplary drugs that may be included in the drug dispensing device described herein include, but are not limited to, immuno-oncology or bio-oncology drugs such as immune checkpoint, cytokine, chemokine, cluster of differentiation, interleukin, integrin, growth factor, coagulation factor, enzyme, enzyme inhibitor, retinoid, steroid, signaling protein, apoptosis-promoting protein, anti-apoptosis protein, T cell receptor, B cell receptor, or costimulatory protein.

[0091] Examples of drugs that can be included in the dispensing device described herein include modulators of human epidermal growth factor receptor 2 (HER-2 receptor), interleukin (IL) modulators, interferon (IFN) modulators, complement modulators, glucagon-like peptide-1 (GLP-1) modulators, glucose-dependent insulinotropic polypeptide (GIP) modulators, cluster of differentiation 38 (CD38) modulators, cluster of differentiation 22 (CD22) modulators, C1 esterase modulators, bradykinin modulators, C-C chemokine receptor type 4 (CCR4) modulators, vascular endothelial growth factor (VEGF) modulators, B cell activating factor (BAFF), P-selectin modulators, neonatal Fc receptor (FcRn) modulators, calcitonin gene-related peptide (CGRP) modulators, epidermal growth factor receptor (EGFR), modulators of cluster of differentiation 79B (CD79B), modulators of tumor-associated calcium signal transducer 2 (Trop-2), modulators of cluster of differentiation 52 (CD52), modulators of B cell maturation antigen (BCMA), enzyme modulators, modulators of platelet-derived growth factor receptor A (PDGFRA), modulators of cluster of differentiation 319 (CD319 or SLAMF7), inhibitors / modulators of programmed cell death protein 1 and programmed death ligand 1 (PD-1 / PD-L1), inhibitors of B lymphocyte antigen cluster of differentiation 19 (CD19), modulators of B lymphocyte antigen cluster of differentiation 20 (CD20), modulators of cluster of differentiation 3 (CD3), inhibitors of cytotoxic T lymphocyte-associated protein 4 (CTLA-4), modulators of T cell immunoglobulin and mucin-containing domain 3 (TIM-3), modulators of T cell immunoreceptor with Ig and ITIM domains (TIGIT), modulators of V domain Ig suppressor of T cell activation (VISTA), modulators of indoleamine 2,3-dioxygenase (IDO or INDO), modulators of poliovirus receptor-related immunoglobulin domain-containing protein (PVRIG), modulators of lymphocyte activation gene 3 (LAG3);Antagonists known also as differentiation cluster 223 or CD223, differentiation cluster 276 (CD276 or B7-H3) antigen modulators, differentiation cluster 47 (CD47) antagonists, differentiation cluster 30 (CD30) modulators, differentiation cluster 73 (CD73) modulators, differentiation cluster 66 (CD66) modulators, differentiation cluster w137 (CDw137) agonists, modulators of differentiation cluster 158 (CD158), modulators of differentiation cluster 27 (CD27), modulators of differentiation cluster 58 (CD58), modulators of cluster 80 (CD80), modulators of differentiation cluster 33 (CD33), modulators of differentiation cluster 159 (CD159 or NKG2), glucocorticoid-induced TNFR-related modulator (GITR) protein modulators, killer Ig-like receptor (KIR) modulators, growth arrest-specific protein 6 (GAS6) / AXL pathway modulators, APRIL (a proliferation-inducing ligand) receptor modulators, human leukocyte antigen (HLA) modulators, epidermal growth factor receptor (EGFR) modulators, B lymphocyte cell adhesion molecule modulators, differentiation cluster w123 (CDw123) modulators, Erbb2 tyrosine kinase receptor modulators, endoglin modulators, mucin modulators, mesothelin modulators, hepatitis A virus cellular receptor 2 (HAVCR2) antagonists, cancer / testis antigen (CTA) modulators, tumor necrosis factor receptor superfamily member 4 (TNFRSF4 or OX40) modulators, adenosine receptor modulators, inducible T cell co-stimulator (ICOS) modulators, differentiation cluster 40 (CD40) modulators, tumor-infiltrating lymphocytes (TIL) or T cell receptor (TCR) therapies, etc. Drugs with proposed mechanisms of action are included, but not limited to these.;

[0092] Examples of drugs that may be included in the dispensing device described herein include, among others, etanercept, abatacept, adalimumab, evolocumab, exenatide, secukinumab, eptinezumab, galsulizumab, fremalizumab-vfrm, alirocumab, methotrexate (amethopterin), tocilizumab, interferon beta-1a, interferon beta-1b, pegylated interferon beta-1a, sumatriptan, darbepoetin alpha, belimumab, sarilumab, semaglutide, dupilumab, reslizumab, omalizumab, glucagon, epinephrine, naloxone, insulin, amylin, vedolizumab, eculizumab, ravulizumab, crisaborole-tmca, certolizumab pegol, satralizumab, denosumab, romosozumab, benralizumab, emicizumab, tildrakizumab, ocrelizumab, ofatumumab, natalizumab, mepolizumab, lisankizumab-RZAA, ixekizumab, and immunoglobulins.

[0093] Examples of drugs that may be included in the dispensing device described herein also include, but are not limited to, ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, semaprimab, rituximab, trastuzumab, ado-trastuzumab emtansine, fam-trastuzumab deruxtecan-nxki, pertuzumab, trastuzumab pertuzumab, alemtuzumab, belantamab mafodotin-blmf, bevacizumab, blinatumomab, brentuximab vedotin, cetuximab, daratumumab, elotuzumab, gemtuzumab ozogamicin, 90-yttrium ibritumomab tiuxetan, isatuximab, mogamulizumab, moxetumomab pasudotox, obinutuzumab, ofatumumab, olaratumab, panitumumab, polatuzumab vedotin, ramucirumab, sacituzumab govitecan, tafasitamab or margetuximab, including tumor treatments.

[0094] Examples of drugs that may be included in the dispensing device described herein include "generic" or biosimilar equivalents of the aforementioned drugs, and the aforementioned molecular names are not intended to limit the "innovative" or "brand" versions of each drug. For example, the innovative drug adalimumab, as well as non-limiting examples of biosimilars such as adalimumab-afzb, adalimumab-atto, adalimumab-adbm, and adalimumab-adaz.

[0095] Exemplary drugs that may be included in the pharmaceutical dispensing device described herein include those used in adjuvant or neoadjuvant chemotherapy such as alkylating agents, plant alkaloids, antitumor antibiotics, antimetabolites, or topoisomerase inhibitors, enzymes, retinoids, or corticosteroids, but are not limited thereto. Exemplary chemotherapeutic drugs include, by way of example and not limitation, 5-fluorouracil, cisplatin, carboplatin, oxaliplatin, doxorubicin, daunorubicin, idarubicin, epirubicin, paclitaxel, docetaxel, cyclophosphamide, ifosfamide, azacitidine, decitabine, bendamustine, bleomycin, bortezomib, busulfan, cabazitaxel, carmustine, cladribine, cytarabine, dacarbazine, etoposide, fludarabine, gemcitabine, irinotecan, leucovorin, melphalan, methotrexate, pemetrexed, mitomycin, mitoxantrone, temsirolimus, topotecan, valrubicin, vincristine, vinblastine, or vinorelbine.

[0096] Examples of drugs that may be included in the dispensing device described herein include analgesics (e.g., acetaminophen), antipyretics, corticosteroids (e.g., hydrocortisone, dexamethasone, or methylprednisolone), antihistamines (e.g., diphenhydramine or famotidine), antiemetics (e.g., ondansetron), antibiotics, preservatives, anticoagulants, fibrinolytic agents (e.g., recombinant tissue plasminogen activator [r-TPA]), antithrombotic agents, or diluents such as sterile water for injection (SWFI), 0.9% saline, 0.45% saline, 5% dextrose in water, 5% dextrose in 0.45% saline, lactated Ringer's solution, heparin lock flush solution, 100 U / mL heparin lock flush solution, or 5000 U / mL heparin lock flush solution, but are not limited thereto.

[0097] Pharmaceutical formulations containing any of the drugs described herein, but not limited thereto, e.g., pharmaceutical formulations containing the drugs (or pharmaceutically acceptable salts thereof) described herein and a pharmaceutically acceptable carrier, are also contemplated for use in the dispensing device described herein. Such formulations may contain one or more other active ingredients (e.g., as a combination of one or more active ingredients), or may be the sole active ingredient, and may also contain dispersing enhancers (e.g., hyaluronidase enzymes of animal, human, or recombinant origin), concentration regulators or enhancers, stabilizers, buffers, or other excipients, administered separately or formulated simultaneously.

[0098] Exemplary drugs that may be included in the drug dispensing device described herein include, but are not limited to, AC, high-dose AC, TCH, GT, EC, TAC, TC, TCHP, CMF, FOLFOX, mFOLFOX6, mFOLFOX7, FOLFCIS, CapeOx, FLOT, DCF, FOLFIRI, FOLFIRINOX, FOLFOXIRI, IROX, CHOP, R-CHOP, RCHOP-21, Mini-CHOP, Maxi-CHOP, VR-CAP, high-dose CHOP, EPOCH, dose-adjusted EPOCH, R-EPOCH, CODOX-M, IVAC, HyperCVAD, R-HyperCVAD, SC-EPOCH-RR, DHAP, ESHAP, GDP, ICE, MINE, CEPP, CDOP, GemOx, CEOP, CEPP, CHOEP, CHP, GCVP, DHAX, CALGB 8811, HIDAC, MOpAD, 7+3, 5+2, 7+4, MEC, CVP, RBAC500, DHA-Cis, DHA-Ca, DHA-Ox, RCVP, RCEPP, RCEOP, CMV, DDMVAC, GemFLP, ITP, VIDE, VDC, VAI, VDC-IE, MAP, PCV, FCR, FR, PCR, HDMP, OFAR, EMA / CO, EMA / EP, EP / EMA, TP / TE, BEP, TIP, VIP, TPEx, ABVD, BEACOPP, AVD, Mini-BEAM, IGEV, C-MOPP, GCD, GEMOX, CAV, DT-PACE, VTD-PACE, DCEP, ATG, VAC, VeIP, OFF, GTX, CAV, AD, MAID, AIM, VAC-IE, ADOC, or PE, among other multi-drug treatment regimens.

[0099] List of reference signs 1 case / box / kit 11 First half shell 12 Second half shell 2 Recesses 21 Tipping point / lever point / pivot point 22 Ribs 23 Removal recess / gripping recess 3 Closure 4 Hinge 5 Drug dispensing device / element of drug dispensing device / component of drug dispensing device 6 corresponding concave portions D distance μ inclination angle

Claims

1. A case (1) for a drug delivery device, said case (1) having a first half shell (11) and a second half shell (12), the half shells (11, 12) are closably connected by a hinge (4), the second half shell (12) being adapted to open and close the first half shell (11); the first half-shell (11) and the second half-shell (12) have a plurality of mutually corresponding recesses (2, 6) configured to receive the drug delivery device (5) or parts of the drug delivery device (5); At least one of the recesses (2) of the first half shell (11) has an inclined point; Case (1), when the drug delivery device (5) or a part of the drug delivery device (5) is received in the recess (2), a distance (d) is formed on one side of the inclined point between the drug delivery device (5) or a part of the drug delivery device (5) and the bottom of the recess (2).

2. The case (1) according to claim 1, wherein the lowest point of at least one of the plurality of recesses (2) is deeper than the inclined point.

3. Case (1) according to claim 1, wherein the inclination point is formed by a rib (22) arranged in the recess (2).

4. 2. The case (1) according to claim 1, wherein a plurality of ribs (22) are arranged in said recess (2), and said inclined points are formed by the contours of said ribs (22).

5. 2. Case (1) according to claim 1, wherein said hinge (4) is a double-living hinge.

6. The case (1) according to claim 1, wherein more than half the volume of the drug delivery device (5) or a part of the drug delivery device (5) is accommodated within the first half shell (11).

7. 2. Case (1) according to claim 1, wherein at least one of the recesses (2), in particular a bottom surface of at least one of the recesses (2), is inclined at an acute angle to the plane of the hinge (4).

8. The case (1) according to claim 1, wherein the case (1) is a hard shell.

9. The case (1) according to claim 1, wherein the case (1) is formed as a single piece.

10. The case (1) according to claim 1, wherein the case (1) is formed by thermoforming or injection molding.

11. The case (1) according to claim 1, wherein the case (1) is transparent or translucent.

12. Case (1) according to claim 1, wherein the first and second half shells (11, 12) can be connected by a snap connection or a latch connection.

13. The inclined points are asymmetrically arranged in the recess (2), Case (1) according to claim 1, wherein the inclined point divides the recess (2) into a longer portion and a shorter portion.

14. Case (1) according to claim 13, wherein said distance (d) is formed in said shorter portion.

15. 2. The case (1) according to claim 1, wherein the recess (2) is adapted to receive an injection device and / or a syringe and / or a cartridge and / or a needle protection device.

16. Case (1) according to claim 15, wherein the recesses (2) each substantially conform to a shape of the injection device and / or syringe and / or cartridge and / or needle protection device.

17. 2. The case (1) according to claim 1, wherein the case (1) has integral markings or writings, the markings or writings being preferably formed during the moulding process.

18. The case (1) according to claim 1, wherein at least one of the plurality of recesses (2) further comprises a laterally arranged removal recess (23) for gripping the drug delivery device (5) or a part of the drug delivery device (5).

Images